Sort   by:  
 Page size 
UnknownPlasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Not available
S-EPMC11869088 | biostudies-literature
UnknownValidating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Not available
S-EPMC10830583 | biostudies-literature
UnknownAdding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Not available
S-EPMC7616360 | biostudies-literature
UnknownDuration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Not available
S-EPMC7616389 | biostudies-literature
UnknownEffects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Not available
S-EPMC11873788 | biostudies-literature
UnknownPatterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry.
Not available
S-EPMC10518516 | biostudies-literature
UnknownComparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Not available
S-EPMC9054878 | biostudies-literature
UnknownMetformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Not available
S-EPMC12303861 | biostudies-literature
Sort   by:  
 Page size